Charles Duncan

Cantor Fitzgerald | Healthcare

Charles Duncan is an analyst from Cantor Fitzgerald specializing in the Healthcare sector. They are beginning to establish their track record, with 1 stock rating so far. Their current stats show a success rate of 67.96% and an average return of 43.24%.

Charles Duncan has only issued 1 rating so far. While the sample size is small, their early calls show a success rate of 67.96% and an average return of 43.24%. Investors may find their initial activity in the Healthcare sector worth watching as they build a track record.

#766

Out of 4773

1

Total Ratings

+67.96%

Success Rate

+43.24%

Average Return

Recent Ratings Analysis

GHRS

May 15, 2026

Target

$35.00

Current

$27.20

Performance

27.16%

Charles Duncan rated GHRS as Overweight on May 15, 2026, setting a price target of 35. The call has proven timely, with shares rising 27.16% toward the price target of 35.

ITCI

Apr 02, 2025

Target

$132.00

Current

$131.87

Performance

—

On Apr 02, 2025, ITCI was given a Neutral rating by Charles Duncan, with a target price of 132. Market indecision, reflected in sideways trading near 131.87, supported the cautious call.

CMPS

Mar 28, 2025

Target

—

Current

$14.35

Performance

388.10%

CMPS received a Overweight rating from Charles Duncan on Mar 28, 2025, aiming for null. Momentum has favored the Buy call, with shares climbing from 14.35 to 14.35, rewarding those who trusted the recommendation.

ACAD

Feb 27, 2025

Target

$28.00

Current

$27.83

Performance

43.90%

On Feb 27, 2025, Charles Duncan published a Overweight outlook on ACAD, with a target of 28. Shares gained 43.90%, underscoring the accuracy of the bullish outlook toward 28.

JAZZ

Feb 26, 2025

Target

$150.00

Current

$245.80

Performance

70.49%

Charles Duncan on Feb 26, 2025 assigned JAZZ a Neutral rating, with a price target of 150. Shares outperformed expectations, climbing 70.49% despite the neutral view.

AXSM

Feb 19, 2025

Target

$153.00

Current

$220.75

Performance

73.87%

On Feb 19, 2025, Charles Duncan reaffirmed AXSM with a Overweight rating, targeting 153. The recommendation was supported by strong follow-through as the stock rose from 220.75 to 220.75.

DRUG

Jan 10, 2025

Target

—

Current

$63.18

Performance

62.46%

DRUG was rated Overweight by Charles Duncan on Jan 10, 2025, with a price objective of null. A bullish response from the market helped close the gap of -63.18 to the target.

BHVN

Dec 17, 2024

Target

—

Current

$12.71

Performance

-67.51%

On Dec 17, 2024, Charles Duncan initiated coverage on BHVN with a Overweight rating and target of null. The Buy call has yet to be validated as shares remain -12.71 away from the target.

STOK

Dec 10, 2024

Target

—

Current

$29.03

Performance

118.93%

Charles Duncan issued a Overweight recommendation for STOK on Dec 10, 2024, price target set at null. Investors following the Buy call captured upside momentum, with shares now at 29.03.

ALKS

Oct 10, 2024

Target

$48.00

Current

$45.97

Performance

67.96%

On Oct 10, 2024, ALKS was evaluated by Charles Duncan, who gave a Overweight rating and target of 48. This case illustrates how a timely bullish rating can translate into tangible gains of 67.96%.

PRTA

Sep 30, 2024

Target

—

Current

$8.93

Performance

-46.62%

Charles Duncan rated PRTA as Overweight on Sep 30, 2024, setting a price target of null. The stock has underperformed, dropping 46.62% despite the bullish target of null.

MRNS

Sep 24, 2024

Target

$13.00

Current

$0.55

Performance

-71.05%

On Sep 24, 2024, MRNS was given a Overweight rating by Charles Duncan, with a target price of 13. Despite the Buy call, shares fell from 0.55 to 0.55, challenging the optimistic stance.

NBIX

Sep 16, 2024

Target

$155.00

Current

$156.22

Performance

27.79%

NBIX received a Overweight rating from Charles Duncan on Sep 16, 2024, aiming for 155. Momentum has favored the Buy call, with shares climbing from 156.22 to 156.22, rewarding those who trusted the recommendation.

KALV

Sep 09, 2024

Target

—

Current

$27.00

Performance

127.46%

On Sep 09, 2024, Charles Duncan published a Overweight outlook on KALV, with a target of null. Shares gained 127.46%, underscoring the accuracy of the bullish outlook toward null.

CYTK

Sep 09, 2024

Target

—

Current

$73.77

Performance

32.13%

Charles Duncan on Sep 09, 2024 assigned CYTK a Overweight rating, with a price target of null. The Buy call aligned well with market performance, producing a gain of 32.13%.

VNDA

Aug 01, 2024

Target

$13.00

Current

$5.09

Performance

-9.75%

On Aug 01, 2024, Charles Duncan reaffirmed VNDA with a Overweight rating, targeting 13. Shares slid 9.75% despite the recommendation, highlighting downside risks.

CYBN

Jul 31, 2024

Target

—

Current

$8.28

Performance

-22.11%

CYBN was rated Overweight by Charles Duncan on Jul 31, 2024, with a price objective of null. This case shows how bullish projections can fail, with the stock now below 8.28.

CGTX

Jul 30, 2024

Target

—

Current

$0.98

Performance

-10.65%

On Jul 30, 2024, Charles Duncan initiated coverage on CGTX with a Neutral rating and target of null. The rating matched the stock’s inability to hold above 0.9828.

MNMD

Jun 21, 2024

Target

—

Current

$20.69

Performance

181.11%

Charles Duncan issued a Overweight recommendation for MNMD on Jun 21, 2024, price target set at null. Investors following the Buy call captured upside momentum, with shares now at 20.69.

ATAI

Jun 21, 2024

Target

—

Current

$7.35

Performance

448.51%

On Jun 21, 2024, ATAI was evaluated by Charles Duncan, who gave a Overweight rating and target of null. This case illustrates how a timely bullish rating can translate into tangible gains of 448.51%.

Frequency Asked Questions

Who is Charles Duncan?

Charles Duncan is an analyst from Cantor Fitzgerald specializing in the Healthcare sector.

What is Charles Duncan's success rate?

Charles Duncan currently has a success rate of +67.96%.

How many ratings has Charles Duncan issued?

Charles Duncan has issued 1 stock ratings so far.

What is the average return of Charles Duncan's calls?

Their stock ratings have generated an average return of +43.24%.

What is Charles Duncan's ranking?

Charles Duncan is ranked #766 out of 4773 analysts.

What types of ratings does Charles Duncan give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Charles Duncan?

You can follow Charles Duncan by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Charles Duncan?

Their latest rating was a Buy on GHRS issued on 2026-05-15.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep